🔴 Neurosense Therapeutics is trading 13.68% down in after-hours trading

Neurosense Therapeutics is trading at $2.02, down 13.68% in after-hours trading, with no verified company-specific catalyst identified.

• On October 20, it fell 12.20% in regular trading, closing at $2.34; price context shows further after-hours weakness.
• The October 19 U.S. patent application covers potential PrimeC use in traumatic brain injury; it is not an issued patent or treatment approval.
• Major U.S. indices finished higher; no trading-volume details were verified.